Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 9/20 | 0.50 |
| ▸ | HSD17B3 | P37058 | 5/20 | 0.45 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.44 |
| ▸ | DAGLA | Q9Y4D2 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13921495 | 0.89 | MEN1 (0.59) | MEN1ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL25335332 | 0.81 | MEN1 (0.49) | MEN1ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL29316552 | 0.81 | MEN1 (0.51) | MEN1ALDH1A1MAPTHTTKMT2A | |
| Hexanoate SCHEMBL28095431 | 0.81 | AKR1B1 (0.46) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL7262412 | 0.80 | CYP1A2 (0.43) | ALDH1A1MAPT | |
| SCHEMBL29316553 | 0.79 | MAPT (0.49) | MEN1ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL13052107 | 0.78 | FAAH (0.50) | MEN1ALDH1A1MAPTHTTKMT2A | |
| Undecane SCHEMBL28275328 | 0.77 | KCNH2 (0.54) | — | |
| SCHEMBL20412757 | 0.76 | FAAH (0.57) | FAAH | |
| SCHEMBL4835374 | 0.74 | ALDH1A1 (0.44) | MEN1ALDH1A1MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230037538-A1 | ANTI-ALS COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230037538-A1 | ANTI-ALS COMPOUNDS | TARDBP, GRN, NLN | MEN1 3946/4885ALDH1A1 3882/4885MAPT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.